Danziten

Active Ingredient(s): Nilotinib Tartrate
FDA Approved: * November 7, 2024
Pharm Company: * AZURITY
Category: Cancer

Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome.[2] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib.[2][3] It is taken by mouth.[3] Common side effects may include low platelets, low white blood cells, anemia... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Danziten 71 mg Oral Tablet
NDC: 24338-154
Labeler:
Azurity Pharmaceuticals, Inc.
Danziten 95 mg Oral Tablet
NDC: 24338-155
Labeler:
Azurity Pharmaceuticals, Inc.

Related Brands

Drugs with the same active ingredients